Thymic carcinoma outcomes and prognosis: Results of an international analysis

Journal of Thoracic and Cardiovascular Surgery

Volumn 149, Issue 1, 2015, Pages 95-101.e2

  Ahmad, Usman ^a   Yao, Xiaopan ^b   Detterbeck, Frank ^b   Huang, James ^a   Antonicelli, Alberto ^b   Filosso, Pier Luigi ^c   Ruffini, Enrico ^c   Travis, William ^a   Jones, David R ^a   Zhan, Yilei ^b   Lucchi, Marco ^d   Rimner, Andreas ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY HOSPITAL OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CARCINOMA; CAUSE OF DEATH; ENDOCRINE TUMOR; FEMALE; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; THYMIC CARCINOMA; TUMOR BIOPSY; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; CLINICAL PRACTICE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY; SEX DIFFERENCE; THYMECTOMY; THYMOMA; THYROID NEOPLASMS; TIME; TREATMENT OUTCOME; TRENDS; TUMOR RECURRENCE;

ADULT; AGED; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHYSICIAN'S PRACTICE PATTERNS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; THYMECTOMY; THYMOMA; THYROID NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84922295451     PISSN: 00225223     EISSN: 1097685X     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2014.09.124     Document Type: Article

References (19)

1. de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ. Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer. 2008;44: 123-30.
2. Greene MA, Malias MA. Aggressive multimodality treatment of invasive thymic carcinoma. J Thorac Cardiovasc Surg. 2003;125:434-6.
3. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann Thorac Surg. 2003;76:878-84.
4. Weksler B, Dhupar R, Parikh V, Nason KS, Pennathur A, Ferson PF. Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients. Ann Thorac Surg. 2013;95:299-303.
5. Detterbeck FC. The International Thymic Malignancy Interest Group. J Natl Compr Canc Netw. 2013;11:589-93.
6. Huang J, Ahmad U, Catlin A, Detterbeck FC; on behalf of the ITMIG International Database Committee. Development of the International Thymic Malignancy Interest Group international database: An unprecedented resource for the study of a rare tumor. J Thorac Oncol. 2014;9:1573-8.
7. Ruffini E, Detterbeck F, Van Raemdonck D, Rocco G, Thomas P, Weder W, et al; on behalf of the European Society of Thoracic Surgeons (ESTS) Thymic Working Group. Tumours of the thymus: a cohort study of prognostic factors from the European Society of Thoracic Surgeons database. Eur J Cardiothorac Surg. 2014;46:361-8.
8. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981;48: 2485-92.
9. Koga K, Matsuno Y, Noguchi M, Mukai K, Asamura H, Goya T, et al. A review of 79 thymomas: modification of staging system and reappraisal of conventional division into invasive and non-invasive thymoma. Pathol Int. 1994;44:359-67.
10. Detterbeck FC, Asamura H, Crowley J, Falkson C, Giaccone G, Giroux D, et al; Staging and Prognostic Factors Committee; Members of the Advisory Boards; Participating Institutions of the Thymic Domain. The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. J Thorac Oncol. 2013;8:1467-73.
11. Lee CY, Bae MK, Park IK, Kim DJ, Lee JG, Chung KY. Early Masaoka stage and complete resection is important for prognosis of thymic carcinoma: a 20-year experience at a single institution. Eur J Cardiothorac Surg. 2009;36: 159-62.
12. Okereke IC, Kesler KA, Freeman RK, Rieger KM, Birdas TJ, Ascioti AJ, et al. Thymic carcinoma: outcomes after surgical resection. Ann Thorac Surg. 2012; 93:1668-72.
13. Ogawa K, Toita T, Uno T, Fuwa N, Kakinohana Y, Kamata M, et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer. 2002;94:3115-9.
14. Hosaka Y, Tsuchida M, Toyabe S, Umezu H, Eimoto T, Hayashi J. Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. Ann Thorac Surg. 2010;89:912-7.
15. Hsu HC, Huang EY, Wang CJ, Sun LM, Chen HC. Postoperative radiotherapy in thymic carcinoma: treatment results and prognostic factors. Int J Radiat Oncol Biol Phys. 2002;52:801-5.
16. Lucchi M, Ambrogi MC, Duranti L, Basolo F, Fontanini G, Angeletti CA, et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg. 2005;79:1840-4.
17. Okuma Y, Hosomi Y, Takagi Y, Sasaki E, Hishima T, Maeda Y, et al. Clinical outcomes with chemotherapy for advanced thymic carcinoma. Lung Cancer. 2013;80:75-80.
18. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. Cancer. 1991;67:1025-32.
19. Yano M, Sasaki H, Yokoyama T, Yukiue H, Kawano O, Suzuki S, et al. Thymic carcinoma: 30 cases at a single institution. Thorac Oncol. 2008;3:265-9.